Radiopharmaceutical preparations: what are the legislative differences across Europe?

Author:

Giustiniani Matteo1,Musazzi Umberto M2ORCID,Minghetti Paola2,Paolino Donatella1ORCID

Affiliation:

1. Department of Experimental and Clinical Medicine, University of Catanzaro “Magna Græcia”, Catanzaro, Italy

2. Department of Pharmaceutical Sciences, Università degli Studi di Milano, Milan, Italy

Abstract

Abstract Objectives Radiopharmaceuticals, since the discovery of the first medical application of radioactive isotope, have been essential therapeutics for the diagnosis and treatment of numerous diseases. Since the Directive 2001/83/EC entered in force, European regulatory authorities have established a harmonised framework to set quality requirements for the industrial production of radiopharmaceuticals. However, little is known about the harmonisation of extemporaneous preparation of radiopharmaceutical preparations (EPRPs) among European countries. In this context, this study aims to provide an overview of the national regulatory framework on the production of EPRPs of five European countries (i.e. UK, Spain, France, Germany and Italy). Methods Five different national regulatory frameworks were compared based on the results of a literature search on electronic databases (i.e. PubMed, Google scholar). Key findings Unlike industrially produced radiopharmaceuticals, the results highlighted that the regulatory framework on EPRPs is still not fully harmonised at the European level and many provisions are regulated by local national laws. Similarities and differences exist among the European countries, both regarding quality standards and educational courses the operators involved in the preparation of EPRPs have to attend. Conclusions The regulatory framework on the EPRPs is still not harmonised at the European level affecting the access to therapies of European citizens who are not equally guaranteed when an extemporaneous radiopharmaceutical has to be prepared to meet their needs.

Publisher

Oxford University Press (OUP)

Subject

Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Economics, Econometrics and Finance (miscellaneous)

Reference25 articles.

1. Regulatory framework of pharmaceutical compounding and actual developments of legislation in Europe;Minghetti;Health Policy.,2014

2. Radiopharmaceuticals regulations: current scenario and the way forward, applied clinical research;Sharma;Clin Trials Regul Aff.,2017

3. Landmarks and landmines in the early history of radiopharmaceuticals;Staum;J Nucl Med Technol.,1992

4. A glance at the history of nuclear medicine;Carlsson;Acta Oncol.,1995

5. Regulatory framework of radiopharmaceuticals: current status and future recommendations;Sharma;Res J Life Sci Bioinform Pharm Chem Sci.,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3